CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 33 enrolled
Drug / intervention
Isotretinoin +1 moredrug
Likely dose
Not stated in record
Key inclusion· 3
  • ✓Age ≥12 years
  • ✓Non-pregnant
  • ✓Severe acne expected to receive isotretinoin for therapeutic reasons
Key exclusion· 16
  • ✕Weight <80 lbs
  • ✕Allergy or adverse reaction to dextromethorphan, vitamin A, or isotretinoin
  • ✕Pregnant or planning pregnancy
  • ✕Unable to comply with isotretinoin iPLEDGE REMS program

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03076021
NCT03076021Phase 4Completed
CompareCT.gov

Effects of Isotretinoin on CYP2D6 Activity

University of Washington·interventional·Posted Mar 9, 2017·Updated Jan 28, 2025

In Brief

A Phase 4 clinical trial evaluating Isotretinoin and dextromethorphan for CYP2D6 Polymorphism. Completed, enrolled 33 participants across 1 site.

Detailed Summary

Specific Aim: To investigate if isotretinoin (13-cis-retinoic acid) administration decreases CYP2D6 activity in adolescent patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCYP2D6 Polymorphism
CountriesUnited States
CollaboratorsNational Institute of General Medical Sciences (NIGMS)

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 9, 2017
Enrollment StartJul 26, 2016
Primary CompletionNov 27, 2023
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 9.3 years ago

Interventions

Isotretinoindrug

Drug interaction study

dextromethorphandrug

Drug interaction study